Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
Healthcare
$3.95 +2.36%
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
52W Low $3.35High $17.94
Volume 1.32M
Average 0.18M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$62.73M
FY 2025 · Annual
Net Income
-$57.59M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 7.17M | 4.48M | 17.36M | 48.94M |
| Selling, General & Admin | 2.7M | 2.17M | 5.31M | 13.79M |
| Operating Expenses | 11.36M | 7.42M | 22.79M | 62.73M |
| Depreciation & Amortization | 110K | 97K | 16K | 36K |
| EBITDA | (10.76M) | (6.56M) | (22.65M) | (57.56M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (11.36M) | (7.42M) | (22.79M) | (62.73M) |
| Operating Margin | — | — | — | — |
| Interest Income | 120K | 1.42M | 2.41M | 5.14M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.2M) | 207K | 2.2M | 5.13M |
| Income Before Tax | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.63) | (0.34) | (0.95) | (2.64) |
| EPS (Diluted) | (0.63) | (0.34) | (0.95) | (2.64) |
| 21.38M | 21.38M | 21.7M | 21.82M | |
| 21.38M | 21.38M | 21.7M | 21.82M |
AARD Earnings Waterfall · TTM
NASDAQ:AARD · Revenue to Net Income
Key Ratios
EPS$-3.21
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$69.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.21, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| 8-K | Current report | Oct 8, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 8, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 |
How much revenue does AARD generate?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported $0.00 of revenue in fiscal 2025.
Is AARD profitable?
Aardvark Therapeutics, Inc. Common Stock (AARD) reported -$57.59M of net income.
Continue the stock analysis
Jump to another research area for this company.